´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ 2019 Pediatric Neurogenetic & Neurometabolic Disease Update : 2019-09-28 |
|
´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ 2019 Pediatric Neurogenetic & Neurometabolic Disease Update : 2019-09-28 ±³À°ÀÏÀÚ : 2019-09-28 ±³À°Àå¼Ò : À̴뼿ﺴ¿ø ´ë°´ç ±³À°ÁÖÁ¦ : 2019 Pediatric Neurogenetic & Neurometabolic Disease Update ÁÖÃÖ±â°ü : ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ ´ã´çÀÚ : ¹Ú¹Ì¼± ¿¬¶ôó : 031-219-4522 À̸ÞÀÏ : ksimd2014@naver.com ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, ½Å°æ¿Ü°ú, ¿µ»óÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°úÀÇ»çÇÐ, »ý¸®ÇÐ, »ýÈÇÐ, ºÐÀÚ»ý¹°ÇÐ, ÀÇ·áÀ±¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇÇб³À° Âü¼®¿¹»óÀοø : 120¸í Èñ¸ÁÆòÁ¡ : 6Á¡ Áö¿ª : ¼¿ïƯº°½Ã ±³À°½Ã°£ : 7 ½Ã°£ 0ºÐ ¼¼ºÎ¼ö°·á : 20,000¿ø ºñ°í Àü¹®ÀÇ 20,000¿ø/Àü°øÀÇ 10,000¿ø ±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±âŸ 09-28 ´ë°´ç 09:00~09:05 Àλ縻 Áøµ¿±Ô(»ï¼º¼¿ïº´¿ø) ±³À°½Ã°£ 09-28 ´ë°´ç 09:05~09:25 Neurometabolic disorders in children, Introduction ÀÌÁöÈÆ(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 09-28 ´ë°´ç 09:25~09:50 Neonatal screening for neurometabolic disorders ÀÌÁ¤È£(¼øõÇâÀÇ´ë) ±³À°½Ã°£ 09-28 ´ë°´ç 09:50~10:15 Interpretation and DDx based on routine laboratory tests and metabolic workups À̹üÈñ(¿ï»êÀÇ´ë) ±³À°½Ã°£ 09-28 ´ë°´ç 10:15~10:40 Genetic diagnosis for neurometabolic disorders ÀÓº´Âù(¼¿ïÀÇ´ë) ±³À°½Ã°£ 09-28 ´ë°´ç 10:40~11:05 Imaging of neuromebabolic disorders Â÷ÁöÈÆ(¿¬¼¼ÀÇ´ë) ÈÞ½Ä 09-28 ´ë°´ç 11:05~11:20 Coffee break () ±³À°½Ã°£ 09-28 ´ë°´ç 11:20~11:40 Emergency treatment for neurometabolic disorders ÀüÁ¾±Ù(ºÎ»êÀÇ´ë) ±³À°½Ã°£ 09-28 ´ë°´ç 11:40~12:00 Diet therapy for neurometabolic disorders ±èÀ¯¹Ì(Ãæ³²ÀÇ´ë) ±³À°½Ã°£ 09-28 ´ë°´ç 12:00~12:20 Therapeutic strategies for lysosomal storage disorders Á¶¼ºÀ±(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 09-28 ´ë°´ç 12:20~12:40 Gene therapy for neurometabolic disorders Á¤¼ºÃ¶(ÀÌÈÀÇ´ë) ±³À°½Ã°£ 09-28 ´ë°´ç 12:40~13:00 Cell therapy for neurometabolic disorders Çѽ¹Î(¿¬¼¼ÀÇ´ë) ½Ä»ç 09-28 ´ë°´ç 13:00~14:00 Lunch () ±³À°½Ã°£ 09-28 ´ë°´ç 14:00~14:25 Metabolic Evaluation of Epilepsy: A Diagnostic Algorithm With Focus on Treatable Conditions °í¾Æ¶ó(ºÎ»êÀÇ´ë) ±³À°½Ã°£ 09-28 ´ë°´ç 14:25~14:50 Final hope for neuronal ceroid lipofuscinosis? Novel treatment targets and strategies º¯Á¤Çý(°í·ÁÀÇ´ë) ±³À°½Ã°£ 09-28 ´ë°´ç 14:50~15:15 Approach to adrenoleukodystrophy and current management guidelines and prospects °ÈÆö(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 09-28 ´ë°´ç 15:15~15:40 Genetic diagnosis and management of mitochondrial disorders ÀÌ¿µ¸ñ(¿¬¼¼ÀÇ´ë) ÈÞ½Ä 09-28 ´ë°´ç 15:40~16:00 Coffee break () ±³À°½Ã°£ 09-28 ´ë°´ç 16:00~16:25 Overview of acid sphingomyelinase deficiency (ASMD) ¼Õ¿µ¹è(¾ÆÁÖÀÇ´ë) ±³À°½Ã°£ 09-28 ´ë°´ç 16:25~16:50 Glutaric aciduria, proposed recommendations for diagnosis and management ±è¼öÁø(ÇѾçÀÇ´ë) ±³À°½Ã°£ 09-28 ´ë°´ç 16:50~17:15 Dopa-responsive dystonia with different causes ¿°¹Ì¼±(¿ï»êÀÇ´ë) ±³À°½Ã°£ 09-28 ´ë°´ç 17:15~17:40 Treatable metabolic myopathies °íÁ¤¹Î(¼¿ïÀÇ´ë) |
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|